Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616902 · ClinicalTrials.gov registry record · Phase 3
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
A Phase 3 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT00616902 is a Phase 3 study that was terminated before completion, run by Abbott. The registered enrollment target is 12 participants.
The verdict
NCT00616902, a Phase 3 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
Interventions
- DRUG paricalcitol injection 4 mcg/mL
- DRUG Placebo Injection 4 mcg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616902
The ClinicalTrials.gov registry entry for NCT00616902 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paricalcitol injection 4 mcg/mL is the first listed.
NCT00616902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616902 about?
NCT00616902 is a clinical study titled "The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5". To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
What is the current status of trial NCT00616902?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2009-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00616902?
The interventions under investigation include: paricalcitol injection 4 mcg/mL (DRUG), Placebo Injection 4 mcg/mL (DRUG).
Who is sponsoring clinical trial NCT00616902?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.